CBER FDA Director - Search News

Order byBest matchMost fresh

Peter Marks, FDA and vaccine

Fierce Pharma · 8h

As FDA's Peter Marks resigns, industry watchers size up vaccine, cell and gene therapy hits

As the FDA wavers from cuts, changes and departures under the second Trump administration, another vital figure of the agency is heading for the exit. | In resigning as director of the FDA’s Center for Biologics Evaluation and Research,

Peter Marks, FDA’s top vaccine regulator, forced out

Top FDA official Peter Marks was forced to resign as the director of the Center for Biologics Evaluation and Research.

Marks’ departure intensifies regulatory uncertainty at US FDA

Peter Marks’ March 28 letter giving one week’s notice of his resignation as director of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) is sending more ripples of uncertainty throughout the industry.

1hon MSN

New FDA commissioner signed off on vaccine chief’s ouster: Reports

Commissioner Marty Makary signed off on the plan to push out the agency’s top vaccine official, Peter Marks, in one of his ...

Marks’ Sudden Departure From FDA Magnifies Uncertainty, Sends Biopharma Shares Down

The stock market—and biotech insiders—reacted negatively to the allegedly forced resignation of CBER Director Peter Marks, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results